Valeant under criminal investigation over Philidor ties: WSJ

With Valeant’s management assuring investors that the company is well on its way to a turnaround, the drugmaker’s problems aren’t supposed to be growing larger. But now, Valeant is facing what could be its most serious investigation yet.

Federal prosecutors are probing the Canadian drugmaker’s relationship with specialty pharmacy Philidor, The Wall Street Journal’s sources say. And while that relationship has already garnered plenty of attention from investigators, media and Wall Street, this particular set of allegations--which claim Valeant defrauded insurers by hiding its close Philidor ties--is new.

The new probe could also be a bigger threat. Philidor managers and Valeant itself might face criminal charges, the WSJ notes.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"We have been fully cooperating with the authorities throughout the investigation, and we are in frequent contact and continue to cooperate with the U.S. Attorney’s Office for the Southern District of New York," Valeant said in a statement.

Prosecutors are looking into whether the specialty pharmacy made false statements to insurers about its link to the drugmaker. They’re trying to figure out whether insurers thought Philidor--which helped patients snag insurance coverage for pricey Valeant meds--was neutral, rather than in Valeant’s service.

And Philidor’s business practices, which include the use of rebates and other compensation to Valeant customers, are also under the lens. The specialty pharmacy is now dead after Valeant severed ties with it last year.

As Philidor’s lawyers wrote in an April letter to a Senate committee, the pharmacy’s conduct was “agnostic” to its ties to Valeant, and it doled out meds that “mirrored the independent judgment” of prescribing doctors, the newspaper notes.

But if government lawyers determine otherwise, both Valeant and Philidor’s execs could find themselves contending with criminal action, the Journal source said. And as Wells Fargo analyst David Maris pointed out in a Thursday note to clients, considering Valeant’s debt mountain--a vestige of its days as a serial buyer--“the impact of financial or commercial penalties is high.”

Valeant, which first came under fire for its Philidor ties last October--when a short seller accused the company of using Philidor to inflate its top line--is already under investigation by state attorneys general, the IRS, the SEC and others. But new CEO Joseph Papa has assured investors that things are turning around at the company. He has also promised to improve transparency.

Some analysts, though, aren’t convinced--including Maris, who earlier this week brought to light that influential Valeant board member Bill Ackman had attended an investor discussion during the company’s pre-earnings quiet period. “Are things really changing, or is it just new paint on the same old shed?” he asked Papa on the company’s Q2 conference call.

Shareholders apparently have their doubts, too. Valeant's stock dove 9.6% in premarket trading Thursday.

- read the WSJ story (sub. req.)

Related Articles:
'Same old Valeant'? Ackman's presence at quiet-period investor meeting draws fire
Is Valeant really stabilizing? With Q2 misses, analysts aren't convinced
Valeant files overdue 10-K, makes sweeping board changes in push for turnaround
Valeant investors, shocked by lightweight guidance, aren't buying CEO Pearson's recovery plans
Pressed by reporters, Valeant 'fesses up to SEC investigation
Another snafu for Valeant as internal probe triggers restated earnings
Valeant cuts ties with shadowy pharmacy Philidor
Valeant shares nosedive on short seller's 'phantom sales' allegations

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.